October 31, 2016
The annual shareholders' meeting on May 10, 2016, resolved that a Nomination Committee shall be appointed before coming election and remuneration. The Nomination Committee shall comprise three members, which should be representative for the two largest shareholders as of last September, together with the Chairman of the Board of Directors.
On September 30, 2016, the two owners controlling the largest number of votes, which desired to appoint a representative to the Nomination Committee, were Jørgen Drejer and Thomas Feldthus. Each such shareholder has appointed a representative, as shown below, who together with the Chairman of the Board of Directors will form Saniona AB's Nomination Committee.
The Nomination Committee's member are:
The Nomination Committee's overall responsibility is to present the following proposals for approval by the 2017 Annual General Meeting:
The Rules and Procedure for the Nomination Committee in Saniona AB can be found in the Corporate Governance section at the company's website, www.saniona.com .
Saniona AB's Annual General Meeting will be held at Setterwalls Advokatbyrå AB's office, Stortorget 23, Malmö, Sweden at 16:00 CET on Tuesday May 23, 2017.
Shareholders who would like to submit proposals to the Nomination Committee can do so via e-mail to firstname.lastname@example.org marked "Recommendation to the Nomination Committee" or by ordinary mail to the address:
Recommendation to the Nomination Committee
Att. Thomas Feldthus
For more information, please contact
Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957, E-mail: email@example.com
This information is information that Saniona (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14:45 CET on October 31, 2016.
Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. The research is focused on ion channels, which makes up a unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona has ongoing collaboration agreements with Boehringer Ingelheim GmbH, Upsher-Smith Laboratories, Inc., Productos Medix, S.A de S.V and Saniona's Boston based spinout Ataxion Inc., which is financed by Atlas Venture Inc. and Biogen Inc. Saniona is based in Copenhagen, Denmark, where it has a research center of high international standard. Saniona is listed at Nasdaq First North Premier and has about 4,400 shareholders. Pareto Securities is Certified Advisor for Saniona. The company's share is traded under the ticker SANION. Read more at www.saniona.com .